Head-to-Head · GLP-1 vs Dual GIP/GLP-1

Semaglutide

Ozempic

GLP-1 receptor agonist
FDA approved 2017 (T2D)

Tirzepatide

Mounjaro

Dual GIP + GLP-1 agonist
FDA approved 2022 (T2D)

GLP-1 vs Dual GIP/GLP-1 — Full Comparison

Q: What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy both contain semaglutide — the same active ingredient — but they are FDA-approved for different indications. Ozempic is approved for type 2 diabetes management. Wegovy is approved specifically for chronic weight management in adults with obesity or overweight with a weight-related condition. They are available in different pen strengths. Your insurance coverage and prescriber's recommendation will typically determine which formulation is prescribed based on your clinical situation.

Q: Why are Ozempic and Mounjaro so expensive?

Both drugs are brand-name only — no generic versions are currently available. The list prices reflect the cost of the underlying biological manufacturing process (both are injectable peptide drugs), ongoing patent protection, and high commercial demand driven by their weight loss efficacy. Insurance coverage varies widely: some plans cover them for diabetes but not weight management, or require prior authorization, or have quantity limits. Manufacturer savings programs may help eligible patients. Neither drug has a generic equivalent approved in the United States as of 2025.

Q: Can you switch from Ozempic to Mounjaro?

Yes — switching between semaglutide and tirzepatide is done in clinical practice, but it should always be managed by your prescriber. The transition approach — including timing and starting strength for the new medication — depends on your current regimen, how long you've been on it, your tolerability, and your clinical goals. Never stop or start either medication without prescriber guidance. Insurance coverage for the new drug and any required prior authorization also needs to be arranged before switching.

Ozempic and Mounjaro belong to the same therapeutic neighborhood — injectable medications that lower blood sugar and produce meaningful weight loss — but they work through different receptor targets. Mounjaro is the first drug approved that activates both GIP and GLP-1 receptors simultaneously, and that dual mechanism appears to translate into greater average weight reduction in clinical trials.

The key mechanistic difference: Ozempic (semaglutide) mimics GLP-1, a hormone released after eating that tells the pancreas to release insulin, slows gastric emptying, and reduces appetite. Mounjaro (tirzepatide) does all of that — and also activates GIP receptors, a second gut hormone involved in glucose-dependent insulin secretion and fat cell metabolism. The GIP receptor activity appears to amplify weight loss beyond what GLP-1 agonism alone achieves.

Ozempic: weekly injection Mounjaro: weekly injection Both: prescription only Both: no generic available

Side-by-side comparison

Ozempic vs Mounjaro at a Glance

Scroll horizontally on small screens. "Edge" column indicates which drug has the advantage in each category based on available evidence.

Category	Ozempic (semaglutide)	Mounjaro (tirzepatide)	Edge
Mechanism Receptor targets	GLP-1 agonist	GIP + GLP-1 dual agonist	Different
FDA Approval Type 2 diabetes	2017	2022	Ozempic longer track record
Weight Loss Brand Same active ingredient	WegovyFDA approved 2021	ZepboundFDA approved 2023	Both available
Average Weight Loss Trial data	Clinically meaningful; STEP trials showed ~15% body weight reduction (Wegovy)	Greater average reduction; SURMOUNT trials showed up to ~21% body weight; superior vs semaglutide in SURMOUNT-5	Mounjaro trial data
Blood Sugar (A1c) Reduction in trials	Excellent; significant A1c reduction in SUSTAIN trials	Slightly greater A1c reduction vs semaglutide in head-to-head data	Mounjaro slight edge
Cardiovascular Data Outcome trials	SELECT trial (2023): reduced major CV events in non-diabetic obesity	SURMOUNT-MMO trial ongoing; CV outcome data not yet published	Ozempic more data
Available Pen Strengths Injection pens	0.5 mg, 1 mg, 2 mg pens	2.5, 5, 7.5, 10, 12.5, 15 mg pens	Different
Route & Frequency	Weekly subcutaneous injection	Weekly subcutaneous injection	Same
Generic Available	No	No	Neither
Black Box Warning	Thyroid C-cell tumors	Thyroid C-cell tumors	Both

All comparison points are based on published clinical trial data and FDA labeling. Individual patient outcomes vary. Available pen strengths shown; dosing decisions are made by your prescriber.

Individual drug profiles

Each Drug in Depth

Semaglutide Ozempic (diabetes) · Wegovy (weight loss)

FDA Approved 2017 (T2D)

GLP-1 Agonist Type 2 Diabetes Weight Management Weekly Injection

Semaglutide is a GLP-1 receptor agonist — it binds to and activates the same receptors as glucagon-like peptide 1, a hormone your gut releases in response to food. By mimicking GLP-1, semaglutide signals the pancreas to release insulin in a glucose-dependent manner (reducing the risk of hypoglycemia compared to older diabetes drugs), slows the rate at which food moves from the stomach into the intestine, and acts on brain areas that regulate appetite and satiety.

Ozempic was the first version approved, indicated for improving blood sugar control in adults with type 2 diabetes and, importantly, for reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Wegovy, approved later at a different pen strength range, is indicated specifically for chronic weight management.

The SELECT cardiovascular outcomes trial (2023) was a landmark: it demonstrated that semaglutide reduced the risk of heart attack, stroke, and cardiovascular death in people with obesity but without diabetes — the first GLP-1 medication to demonstrate this benefit in a non-diabetic population, substantially expanding the evidence base for the drug class.

Ozempic is available in 0.5 mg, 1 mg, and 2 mg pens. Wegovy is available in its own pen strength range for the weight management indication.

Black box warning

Both Ozempic and Wegovy carry an FDA black box warning for thyroid C-cell tumors based on animal studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

More CV outcome data than any GLP-1: Semaglutide has the most extensive published cardiovascular outcomes data in the class, including SELECT (non-diabetic obesity), SUSTAIN-6, and SOUL trial results. This is a meaningful advantage for patients where cardiovascular risk is a primary concern.

Tirzepatide Mounjaro (diabetes) · Zepbound (weight loss)

FDA Approved 2022 (T2D)

Dual GIP + GLP-1 Type 2 Diabetes Weight Management Weekly Injection

Tirzepatide is the first in a new class: a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. In a single molecule, it activates both receptor types — and this is not simply additive. GIP and GLP-1 signaling interact in ways that appear to produce greater weight loss than GLP-1 agonism alone. GIP receptors are expressed in fat tissue and the brain, and their activation may enhance the appetite-suppressing and fat-mobilizing effects beyond what GLP-1 can do by itself.

The SURMOUNT clinical trial program established tirzepatide's efficacy for weight management, with SURMOUNT-1 showing up to approximately 21% mean body weight reduction. Crucially, SURMOUNT-5 directly compared tirzepatide to semaglutide head-to-head in adults with obesity without diabetes — tirzepatide produced significantly greater weight loss. This makes Mounjaro/Zepbound the higher-efficacy option for maximum weight reduction based on current evidence.

Mounjaro is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pens. Zepbound uses the same pen strengths for the weight management indication.

Black box warning

Mounjaro and Zepbound carry the same FDA black box warning as semaglutide — thyroid C-cell tumors observed in animal studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Cardiovascular outcomes data pending: The SURMOUNT-MMO cardiovascular outcomes trial for tirzepatide is ongoing. Until those results are published, tirzepatide lacks the long-term CV outcome evidence that semaglutide has accumulated — a relevant consideration for patients with established or high cardiovascular risk.

Applies to both drugs

Common Side Effects

Ozempic and Mounjaro share a very similar side effect profile. The GI effects are the most common reason people reduce or discontinue either medication. Talk to your prescriber about anything that affects your quality of life.

Nausea & Vomiting

The most commonly reported side effects for both drugs. Tend to be most intense when starting or after a strength increase, and typically improve over several weeks as the body adjusts. Eating smaller meals and avoiding high-fat foods can help.

Diarrhea & Constipation

GI motility changes affect people differently — some experience diarrhea, others constipation. Both are common in the first weeks of treatment. Staying hydrated, eating adequate fiber, and moving the body regularly can help manage either pattern.

Injection Site Reactions

Mild redness, bruising, or soreness at the injection site can occur with either drug. Rotating injection sites and allowing the pen to reach room temperature before injecting generally reduces these reactions.

Fatigue

Some patients report fatigue, particularly during the early weeks of treatment or after strength adjustments. This typically resolves as the body adapts. Reduced calorie intake — a desired effect — can also contribute to lower energy levels initially.

Heart Rate Increase

Both drugs can cause a modest increase in resting heart rate. For most patients this is not clinically meaningful, but it is worth monitoring. Your prescriber may check your heart rate periodically, particularly if you have underlying cardiac conditions.

Pancreatitis Risk

Cases of acute pancreatitis have been reported with GLP-1 medications. Symptoms include severe abdominal pain that may radiate to the back, often with nausea and vomiting. If you experience these symptoms, stop the medication and seek medical attention immediately.

Shared contraindications: Both Ozempic and Mounjaro are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — see the black box warning on each drug. Neither should be used in combination with other GLP-1 receptor agonists. Both have been associated with serious side effects including gallbladder disease, acute kidney injury (secondary to dehydration from GI effects), and diabetic retinopathy complications. Your prescriber will review your full medical history before prescribing.

Clinical verdict

Which One Is Right for You?

No single answer applies to every patient. Below is a summary of where each drug has a clinical edge — the right choice depends on your goals, cardiovascular risk, insurance coverage, and what your prescriber determines after reviewing your full history.

Goal: Maximum weight loss

Greater average reduction in trials

SURMOUNT-5 showed tirzepatide produced significantly greater weight loss than semaglutide head-to-head in patients with obesity. If maximum average weight reduction is the primary goal, current trial data favors Mounjaro/Zepbound.

→ Mounjaro edge

Goal: Cardiovascular protection

More outcome trial data published

Ozempic (semaglutide) has the SELECT trial demonstrating CV benefit in non-diabetic obesity, plus SUSTAIN and SOUL data in diabetes. Mounjaro's SURMOUNT-MMO results are pending. For patients where CV risk is central, semaglutide has a stronger evidence base today.

→ Ozempic edge

Goal: Blood sugar control

Both excel; tirzepatide slightly ahead

Both drugs produce excellent A1c reduction in people with type 2 diabetes. Head-to-head comparisons show tirzepatide achieving slightly greater A1c lowering on average — but both are highly effective and either may be appropriate depending on baseline A1c and other factors.

→ Mounjaro slight edge

Consideration: Track record

Longer real-world experience

Ozempic has been in use since 2017 — several years of post-market data on long-term tolerability, rare adverse events, and real-world outcomes. Mounjaro was approved in 2022. For patients who value a longer safety track record, semaglutide has the advantage.

→ Ozempic edge

Consideration: Coverage & cost

Highly variable — check your plan

Both drugs are brand-name only with high list prices. Insurance coverage depends on your plan, your diagnosis (diabetes vs obesity), and whether prior authorization is required. Supply shortages have affected both at various times. Neither has a generic equivalent available.

→ Depends on your insurer

Diagnosis: Type 2 diabetes + obesity

Both are excellent choices

For patients with type 2 diabetes and obesity, both Ozempic and Mounjaro are appropriate first-line options. Your prescriber will weigh your A1c, cardiovascular risk, other medications, insurance coverage, and personal preferences to make an individualized recommendation.

→ Discuss with your prescriber

Frequently asked questions

Common Questions

Is Mounjaro more effective than Ozempic for weight loss?

In head-to-head clinical trials — particularly the SURMOUNT-5 trial — tirzepatide (Mounjaro/Zepbound) produced greater average body weight reduction than semaglutide (Ozempic/Wegovy). This likely reflects tirzepatide's dual GIP and GLP-1 receptor mechanism: activating both receptor types appears to produce additive or synergistic effects on weight regulation beyond what GLP-1 agonism alone achieves. That said, both drugs produce clinically meaningful weight loss in the majority of patients. Individual results vary considerably based on adherence, diet, activity level, genetics, and other factors. Neither drug is a substitute for discussing your personal situation with your prescriber.

What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy both contain semaglutide — the identical active ingredient — but they are FDA-approved for different indications and available in different pen strength ranges. Ozempic is indicated for improving blood sugar control in adults with type 2 diabetes and for reducing cardiovascular events in adults with type 2 diabetes and established heart disease. Wegovy is indicated specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. Your insurance plan may cover one but not the other depending on your diagnosis. Your prescriber will determine which formulation is appropriate based on your clinical situation.

What is the difference between Mounjaro and Zepbound?

Mounjaro and Zepbound both contain tirzepatide — the same active ingredient, and the same available pen strengths (2.5 mg through 15 mg). The difference is their FDA-approved indication. Mounjaro is approved for improving blood sugar control in adults with type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. They are prescribed and covered differently by insurance plans — some plans cover Mounjaro for diabetes but not Zepbound for weight loss. Discuss with your prescriber and insurance plan to understand which formulation your situation and coverage supports.

Why are Ozempic and Mounjaro so expensive?

Both drugs are still under patent protection — no generic or biosimilar versions are currently approved in the United States. The list prices reflect the complex biological manufacturing process required to produce injectable peptide drugs at scale, ongoing research and development costs, and high commercial demand. Insurance coverage varies significantly: some plans cover these drugs for their diabetes indications but not for weight management, or require prior authorization, step therapy, or quantity limits. Manufacturer patient assistance programs and savings cards may help eligible patients reduce out-of-pocket costs. It is worth having a dedicated conversation with your prescriber and insurance plan about coverage before starting either medication.

Can you switch from Ozempic to Mounjaro?

Yes — transitions between semaglutide and tirzepatide do happen in clinical practice, particularly when a patient has not achieved their glycemic or weight loss goals on one medication, or when insurance coverage changes. However, switching should always be managed by your prescriber. They will determine the timing of the transition, what pen strength to start on for the new drug, and how to monitor your response. There is no standard universal protocol — the approach depends on how long you've been on the current medication, your current pen strength, your tolerability, and your clinical goals. Never stop or adjust either medication without prescriber guidance, and make sure any insurance prior authorization for the new drug is in place before making the switch.

Related Guides

→

Diabetes Medications Compared

→

How GLP-1 Medications Work

→

Semaglutide Drug Profile

→

Empagliflozin Drug Profile

Medical disclaimer

Important notice

This page is designed for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Ozempic, Wegovy, Mounjaro, and Zepbound are prescription medications that should only be started, stopped, or adjusted under the supervision of a qualified prescriber who knows your complete medical history. Dosing decisions are made by your prescriber based on your individual clinical situation — pen strengths noted on this page describe available formulations, not recommended doses. Individual responses to these medications vary significantly. Clinical trial results represent population averages and may not predict your personal outcome. If you are experiencing a medical emergency, call 911. For questions about your medications, contact your prescriber or pharmacist. Poison Control: 1-800-222-1222.